key: cord-0774180-5f5npz07 authors: Manning, Jessica; Zaidi, Irfan; Lon, Chanthap; Rosas, Luz Angela; Park, Jae-Keun; Ponce, Aiyana; Bohl, Jennifer; Chea, Sophana; Karkanitsa, Maria; Sreng, Sokunthea; Rekol, Huy; Chour, Char Meng; Esposito, Dominic; Taubenberger, Jeffery K.; Memoli, Matthew J.; Sadtler, Kaitlyn; Duffy, Patrick E.; Oliveira, Fabiano title: SARS-CoV-2 Cross-Reactivity in Prepandemic Serum from Rural Malaria-Infected Persons, Cambodia date: 2022-02-03 journal: Emerg Infect Dis DOI: 10.3201/eid2802.211725 sha: e0d290b8bb960f2edcc8681c02487060f189e1f7 doc_id: 774180 cord_uid: 5f5npz07 Inhabitants of the Greater Mekong Subregion in Cambodia are exposed to pathogens that might influence serologic cross-reactivity with severe acute respiratory syndrome coronavirus 2. A prepandemic serosurvey of 528 malaria-infected persons demonstrated higher-than-expected positivity of nonneutralizing IgG to spike and receptor-binding domain antigens. These findings could affect interpretation of large-scale serosurveys. Inhabitants of the Greater Mekong Subregion in Cambodia are exposed to pathogens that might infl uence serologic cross-reactivity with severe acute respiratory syndrome coronavirus 2. A prepandemic serosurvey of 528 malaria-infected persons demonstrated higher-thanexpected positivity of nonneutralizing IgG to spike and receptor-binding domain antigens. These fi ndings could aff ect interpretation of large-scale serosurveys. values (calibrated for the Mali or US populations) were used for this assay (4,12,13) (Table; Figure 1 ; Appendix Table 1 , https://wwwnc.cdc.gov/EID/ article/28/2/21-1725-App1.pdf). To test whether the higher-than-expected positivity was an artifact of our in-house ELISA, we tested a subset of samples with a commercially validated SARS-CoV-2 Spike S1-RBD IgG ELISA Detection Kit (Genscript, https://www.genscript.com). Of the 24 persons who were seronegative by in-house assay and 11 who were seropositive by in-house assay, 18 tested negative and 9 tested positive by the commercial test, yielding an overall concordance of 77.1% between assays (Appendix Table 2 ). This inconsistency might be explained by the stringency of the in-house assay that tests both spike and RBD versus the commercial kit that tests for RBD only; nevertheless, higher-than-expected positivity was observed in both assays. Because common cold coronaviruses do circulate in Cambodia, but no cases of SARS-CoV-1 or Middle East respiratory syndrome have been documented, we tested a subset of the cohort for IgG to HKU1 and OC43. Reactivity between subjects was comparable despite SARS-CoV-2 serostatus ( Figure 2 , panel A). We further tested 289 samples to assess whether a relationship existed between antibodies to Plasmodium spp. and SARS-CoV-2 proteins by using 2 known malarial antigens: Plasmodium falciparum apical membrane antigen 1 (AMA-1), which is highly immunogenic and an indicator of parasite exposure, and P. falciparum Pfs25 protein (Pfs25), which is poorly immunogenic and expressed only during As expected, no difference was seen in antibody levels to Pfs25 with regard to SARS-CoV-2 seropositivity (Figure 2 , panel C). A weak but statistically significant positive correlation was detected between spike and RBD with AMA-1 IgG (Figure 2 , panel D). This finding corroborates recent observations that higher SARS-CoV-2 seroreactivity by ELISA or rapid tests is detected in persons from malaria-endemic areas, expanding previous observations to include Southeast Asia (7,8; S. Lapidus et al., unpub. data). We also evaluated samples for seroreactivity against the nucleocapsid protein that also positively correlated with the AMA-1 IgG. Only nucleocapsid antibodies were weakly correlated with Pfs25 antibodies, which reinforces the argument for nonspecific nucleocapsid reactivity ( Figure 2 , panel E). Preincubation with 10 mg/mL of AMA-1 or bovine serum albumin had no notable effect on reactivity to SARS-CoV-2 spike S1-RBD ( Figure 2, Africa was mitigated by the modification of 2 commercial assays to add a urea wash (S. Lapidus et al., unpub. data). To elucidate the functionality of the detected antibodies, we took a subset (n = 21) of the samples with the highest reactivity to SARS-CoV-2 total IgG and performed neutralization assays (Appendix Figure) . No neutralizing activity was identified despite high levels of antibodies reacting to both spike and RBD proteins. Identical results were obtained by using a surrogate virus neutralization test targeting RBD interaction with the host cell receptor ACE2 (Genscript) (Appendix Table 3 ) (14) . Both SARS-CoV-2 infection and vaccination can trigger high levels of nonneutralizing antibodies, whereas neutralizing antibodies aimed primarily at the RBD seem to wane faster and remain at low titers (14) . Plausibly, the cross-reactive nonfunctional antibodies to SARS-CoV-2 were raised during an infection by Plasmodium spp. (S. Lapidus et al., unpub. data), but we cannot discard the hypothesis that nonneutralizing SARS-CoV-2-reactive antibodies in prepandemic serum samples might be linked to the ability of betacoronaviruses to evade immune recognition because of their complex surfaces (14, 15) . A limitation in understanding the assays' specificity is the lack of prepandemic samples from non-malaria-endemic areas and from presentday confirmed SARS-CoV-2 convalescent samples in Cambodia. We found in a widely used, highly specific, and validated ELISA that ≈4%-14% of prepandemic serum samples from malaria-infected persons in Cambodia were positive for nonneutralizing antibodies to SARS-CoV-2 spike and RBD antigens by using various standardized optical density cutoff values (4, 12, 13) . We noted a relationship between increased SARS-CoV-2 seroreactivity and antimalarial humoral immunity, which was also recently shown in Africa (S. Lapidus et al., unpub. data). The plausibility of regular spillover events, or simply increased exposure to uncharacterized betacoronaviruses, as a reason for SARS-CoV-2 cross-reactivity is also increased in settings at high risk for zoonotic disease transmission because of agricultural and dietary practices such as bat guano collection and consumption of wild meats (9) (10) (11) . Given that 50%-80% of GMS residents are classified as rural, careful calibration of serologic assays targeting SARS-CoV-2 will be necessary in national and subnational serosurveys. Although neutralization assays with live virus are often considered the standard because of their specificity, they are cost-prohibitive for large-scale serosurveys. The use of competition ELISA assays such as surrogate virus neutralization tests targeting the RBD-ACE2 blockade might be an attractive option for populations at high risk for zoonotic exposures in resource-scarce settings without Biosafety Level Viral and serological testing of SARS-CoV-2 among health care workers and patients in Vietnam Seroprevalence of hospital staff in a province with zero COVID-19 cases Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors Rapidly increasing SARS-CoV-2 seroprevalence and limited clinical disease in 3 Malian communities: a prospective cohort study findings from the second nationwide household serosurvey Preexisting and de novo humoral immunity to SARS-CoV-2 in humans Cross-reactivity of two SARS-CoV-2 serological assays in a setting where malaria is endemic COVID-19 antibody detecting rapid diagnostic tests show high cross-reactivity when challenged with pre-pandemic malaria A novel SARS-CoV-2 related coronavirus in bats from Cambodia Evidence for SARS-CoV-2 related coronaviruses circulating in bats and pangolins in Southeast Asia Coronavirus testing indicates transmission risk increases along wildlife supply chains for human consumption in Viet Nam Standardization of ELISA protocols for serosurveys of the SARS-CoV-2 pandemic using clinical and at-home blood sampling Serologic cross-reactivity of SARS-CoV-2 with endemic and seasonal betacoronaviruses A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction SARS-CoV-2 structural features may explain limited neutralizing-antibody responses We thank the participants of the studies in Pursat, Ratanakiri, and Preah Vihear provinces and the original study protocol staff. Dr. Manning is an infectious diseases physician-scientist focused on vector-borne disease epidemiology. She is currently based in Phnom Penh as an Assistant Clinical Investigator for the National Institute of Allergy and I nfectious Diseases and its International Center of Excellence in Research Cambodia.